Businesswire·2026-01-14 12:27Core Viewpoint - Alto Neuroscience has announced the issuance of U.S. Patent Number 12,521,374 for ALTO-207, a novel treatment for depression that combines pramipexole and ondansetron, aimed at enhancing the efficacy of pramipexole while mitigating its side effects [1][2][3] Group 1: Patent and Intellectual Property - The newly issued patent protects the method of using ondansetron to reduce pramipexole-related side effects, allowing for higher doses to achieve antidepressant benefits [1] - The patent issuance strengthens the intellectual property portfolio of ALTO-207, which is expected to provide protection extending into the mid-2040s, enhancing the long-term commercial opportunity for the program [2][3] Group 2: Product Overview - ALTO-207 is a fixed-dose combination of pramipexole, a dopamine D3-preferring agonist, and ondansetron, an antiemetic, designed to enable rapid titration and higher dosing by mitigating adverse events associated with pramipexole [4] - The product is being developed to address the significant unmet need for patients with treatment-resistant depression [4] Group 3: Clinical Trial Results - In a Phase 2a clinical trial involving 32 patients, ALTO-207 met primary and secondary endpoints, showing significantly greater improvements on the Montgomery-Åsberg Depression Rating Scale (MADRS) compared to placebo [5] - Patients receiving ALTO-207 reached a mean dose of 4.1 mg per day, with an adverse event rate similar to that of the placebo group, indicating good tolerability [5] Group 4: Company Mission and Strategy - Alto Neuroscience aims to redefine psychiatry by developing personalized and effective treatment options, leveraging neurobiology and a Precision Psychiatry Platform that analyzes various brain biomarkers [6] - The company is focused on building a portfolio of differentiated, innovative, precision-driven assets protected by robust intellectual property [3]